2. UroToday Home
  3. Newsletter Archive

ESMO 2021

ESMO 2022 Multidisciplinary Updates in Genitourinary Tumors and Biomarkers in Urinary CancersSent on 15 September 2022
Treatment Management in Prostate Cancer ESMO 2022 HighlightsSent on 13 September 2022
ESMO 2022 Presidential Symposium III in Kidney Cancer Results From the COSMIC-313, RADICALS-HD Trial and Orals in Bladder CancerSent on 12 September 2022
ESMO 2022 Presidential Symposium II in Kidney Cancer Results From the Phase 3 CheckMate 914 Trial and Mini Orals in Bladder CancerSent on 12 September 2022
ESMO 2022 Prostate Cancer Mini Oral Session: Quality of Life in the ARASENS Study, The CABASTY Randomized Phase III Trial, and Preliminary Phase 2 Results of the CYPIDES StudySent on 11 September 2022
ESMO 2022 Late Breaking Abstracts in Prostate Cancer - Overall Survival Results From the STAMPEDE Protocol and PRESTO AFT-19 in High-Risk Biochemically Relapsed Prostate CancerSent on 11 September 2022
ESMO 2022 Highlights - Biomarkers for Advanced Urothelial Carcinoma and Do the Results of the Perioperative Renal Cancer Trials Make SenseSent on 10 September 2022
Join UroToday for Access to ESMO 2022 Congress Highlights Starting Saturday Sept 10Sent on 06 September 2022
Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer in a Prospective Statewide Collaborative Sent on 12 November 2021
Kidney Cancer Association’s International Kidney Cancer Symposium 2021 Meeting Highlights Sent on 07 November 2021
Patient Quality of Life and the Impact of Treatment on Local Symptoms in M0 CRPC Sent on 27 October 2021
Clinical Trials - Aiming to Change the Standard of Care in mCRPC Sent on 22 October 2021
Lutetium-177-Labeled PSMA-Targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerSent on 23 September 2021
ESMO 2021 Real World Treatment Patterns of Metastatic Castration Sensitive Prostate Cancer and Highlights in GU Malignancies Sent on 21 September 2021
ESMO 2021 - Health-Related Quality of Life from the VISION Study and Prostate and Bladder Cancer HighlightsSent on 20 September 2021
ESMO 2021 Late-Breaking Abstracts in Bladder and Kidney Cancer and Highlights in Genitourinary MalignanciesSent on 19 September 2021
ESMO 2021 – Final Overall Survival Analysis From ARCHES, Results of Expanded Cohort 6 of the COSMIC-021 Study and Highlights in Prostate CancerSent on 19 September 2021
ESMO 2021 First Results From the NORSE and GETUG/AFU VESPER V05 Trials and Highlights in Bladder and Kidney CancerSent on 17 September 2021
ESMO 2021 Prostate Cancer Trials in Progress and Session Highlights from Advanced Prostate CancerSent on 16 September 2021
European Society for Medical Oncology (ESMO) 2021 - Expert Written Session Summaries Begin ThursdaySent on 14 September 2021
Display #
Results 1 - 20 out of 20
Send the selected Newsletters to...